The Diagnosis and Treatment of Malignant Tumors of the Kidneys in Adults

Pancreatic cancer (PC) is one of the most common malignant tumors in the digestive tract worldwide, with increased morbidity and mortality. In recent years, with the development of surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy, and the change of the medical thinking model, remarkable progress has been made in researching comprehensive diagnosis and treatment of PC. However, the present situation of diagnostic and treatment of PC is still unsatisfactory. There is an urgent need for academia to fully integrate the basic research and clinical data from PC to form a research model conducive to clinical translation and promote the proper treatment of PC. This paper summarized the translation progress of mass spectrometry (MS) in the pathogenesis, diagnosis, prognosis, and PC treatment to promote the basic research results of PC into clinical diagnosis and treatment.

Download Full-text

Modern Nanomaterials and Nanotechnology in Diagnosis and Treatment of Malignant Tumors of Gastrointestinal Tract

European Journal of Molecular Biotechnology ◽

10.13187/ejmb.2019.2.49 ◽

2019 ◽

Vol 7 (2) ◽

Keyword(s):

Gastrointestinal Tract ◽

Malignant Tumors ◽

Diagnosis And Treatment

Download Full-text

GNG5 is a Novel Oncogene Associated with Poor Prognosis in Glioma Patients

10.21203/rs.3.rs-42547/v1 ◽

2020 ◽

Author(s):

Wang Zhang ◽

Binchao Liu ◽

Miaomiao Jiang ◽

Shi Yan ◽

Xian Han ◽

...

Keyword(s):

Signaling Pathways ◽

Poor Prognosis ◽

Malignant Tumors ◽

Large Data ◽

Diagnosis And Treatment ◽

Receptor Interaction ◽

Sequencing Data ◽

Clinical Prognosis ◽

New Biomarkers ◽

The Relationship

Abstract Background: Although many biomarkers have been reported for detecting glioma, the prognosis for the disease remains poor, and therefore, new biomarkers need to be identified. GNG5, which is part of the G-protein family, has been associated with different malignant tumors, though the role of GNG5 in glioma has not been studied. Therefore, we aimed to identify the relationship between GNG5 expression and glioma prognosis and to identify a new biomarker for the diagnosis and treatment of gliomas.Methods: We used datasets from databases including TCGA and GEO, and results from GEPIA, RT-qPCR, and HPA to determine the expression of GNG5 in glioma. Based on datasets obtained from the CGGA database, we identified the correlation between GNG5 expression and multiple molecular and clinical features as well as clinical prognosis using a variety of analytical methods. Co-expression analysis and GSEA were performed to detect GNG5-related genes in gliomas and possible signaling pathways involved. ESTIMATE, ssGSEA, and TIMER were used to detect the relationship between GNG5 and the immune microenvironment.Results: A total of 1826 glioma related datasets were used in our study, including sequencing data, microarray data, and RT-qPCR data. We found that GNG5 is highly expressed in gliomas, and its expression level is positively correlated with pathological grade, histological type, age, and tumor recurrence and negatively correlated with isocitrate dehydrogenase mutation, 1p/19 co-deletion, and chemotherapy. Moreover, GNG5 as an independent risk factor was negatively correlated with the overall survival time. GSEA analysis revealed the potential signaling pathways involved in GNG5 function in gliomas, such as ECM-receptor interaction and the toll-like receptor signaling pathway. The ssGSEA, ESTIMATE, and TIMER based analysis indicated a correlation between GNG5 expression and various immune cells in glioma, such as B cell, macrophage, and dendritic cells.Conclusions: Based on the large data platform and the use of different databases to corroborate results obtained using various datasets, our study reveals for the first time that GNG5, as an oncogene, is overexpressed in gliomas and can lead to poor prognosis of patients. Thus, GNG5 is a potential novel biomarker for the clinical diagnosis and treatment of gliomas.

Download Full-text

GNG5 is a novel oncogene associated with poor prognosis in glioma patients

10.21203/rs.3.rs-49192/v1 ◽

2020 ◽

Author(s):

Wang Zhang ◽

Binchao Liu ◽

Miaomiao Jiang ◽

Shi Yan ◽

Xian Han ◽

...

Keyword(s):

Signaling Pathways ◽

Poor Prognosis ◽

Malignant Tumors ◽

Large Data ◽

Diagnosis And Treatment ◽

Receptor Interaction ◽

Sequencing Data ◽

Clinical Prognosis ◽

New Biomarkers ◽

The Relationship

Abstract Background: Although many biomarkers have been reported for detecting glioma, the prognosis for the disease remains poor, and therefore, new biomarkers need to be identified. GNG5, which is part of the G-protein family, has been associated with different malignant tumors, though the role of GNG5 in glioma has not been studied. Therefore, we aimed to identify the relationship between GNG5 expression and glioma prognosis and to identify a new biomarker for the diagnosis and treatment of gliomas.Methods: We used datasets from databases including TCGA and GEO, and results from GEPIA, RT-qPCR, and HPA to determine the expression of GNG5 in glioma. Based on datasets obtained from the CGGA database, we identified the correlation between GNG5 expression and multiple molecular and clinical features as well as clinical prognosis using a variety of analytical methods. Co-expression analysis and GSEA were performed to detect GNG5-related genes in gliomas and possible signaling pathways involved. ESTIMATE, ssGSEA, and TIMER were used to detect the relationship between GNG5 and the immune microenvironment.Results: A total of 1826 glioma related datasets were used in our study, including sequencing data, microarray data, and RT-qPCR data. We found that GNG5 is highly expressed in gliomas, and its expression level is positively correlated with pathological grade, histological type, age, and tumor recurrence and negatively correlated with isocitrate dehydrogenase mutation, 1p/19 co-deletion, and chemotherapy. Moreover, GNG5 as an independent risk factor was negatively correlated with the overall survival time. GSEA analysis revealed the potential signaling pathways involved in GNG5 function in gliomas, such as ECM-receptor interaction and the toll-like receptor signaling pathway. The ssGSEA, ESTIMATE, and TIMER based analysis indicated a correlation between GNG5 expression and various immune cells in glioma, such as B cell, macrophage, and dendritic cells.Conclusions: Based on the large data platform and the use of different databases to corroborate results obtained using various datasets, our study reveals for the first time that GNG5, as an oncogene, is overexpressed in gliomas and can lead to poor prognosis of patients. Thus, GNG5 is a potential novel biomarker for the clinical diagnosis and treatment of gliomas.

Download Full-text

Diagnosis and Treatment of Non-epithelial Malignant Tumors in the Anal Region

Nippon Daicho Komonbyo Gakkai Zasshi ◽

10.3862/jcoloproctology.61.998 ◽

2008 ◽

Vol 61 (10) ◽

pp. 998-1003 ◽

Cited By ~ 1

Author(s):

Yoshito Akagi ◽

Kazuo Shirouzu ◽

Nobuya Ishibashi ◽

Tetsushi Kinugasa

Keyword(s):

Malignant Tumors ◽

Diagnosis And Treatment ◽

Anal Region

Download Full-text

Delay in diagnosis and treatment of soft tissue sarcomas (STS): Causes of late intervention and their role in prognosis—A prospective, multidisciplinary group study.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.10055 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. 10055-10055

Author(s):

Alessandro Comandone ◽

Elisa Berno ◽

Antonella Boglione ◽

Cristiano Oliva ◽

Manuela Ingui' ◽

...

Keyword(s):

Median Time ◽

Primary Care Physicians ◽

Malignant Tumors ◽

Soft Tissue Sarcomas ◽

Diagnosis And Treatment ◽

Medical Visit ◽

Anatomic Site ◽

Optimal Care ◽

General Hospitals ◽

Multidisciplinary Group

10055 Background: STS are 1% of malignant tumors in adults. Rarity, heterogeneity in presentation, low expertise in primary care physicians (PCP) or in general hospitals, organisation problems in specialized centers may cause a delay in both diagnosis and treatment. Aim of this study is to acknowledge the barriers to optimal care and the consequences of the delay on prognosis. Methods: Patients with STS of the extremities, trunk, retroperitoneum treated and followed from 1999 to 2011 by the same multidisciplinary group were included. Time and pattern of symptoms onset, anatomic site, tumor volume, patients’ age, gender and home, interval between diagnosis and surgical treatment or neoadjuvant chemotherapy; time to start adjuvant RT or CT were considered in a univariate - multivariate analysis. Results: 449 adult patient (53% F, 47% M, median age 55 years) were followed for a median time of 116.38 months. 65.7% of STS were at the extremities, 17.6% retroperitoneal, 16.7% at the trunk wall. Median volume at diagnosis was 8 cm for trunk and extremities; 15 cm for retroperitoneum. Commonest histologies: liposarcoma. 18.2%; leiomyo 16.8%; mixofibro 13.6%. Increasing mass, pain, and abdominal disconfort were the main revealing signs of diseases. Median time of delay were: from onset of symptom to first medical visit 68 days for trunk and extremities, 82 for retroperitoneum; 104 days from symptoms to histological diagnosis; 129 days from symptoms to start of therapy. Time to surgery after definitive diagnosis was 12 days in extremities and 21 in abdomen. Adjuvant CT started 22 days after surgery for extremities, 25 in trunk, 35 in retroperitoneum. RT initiated after 78 days. Longer delay in treatment lead to worse prognosis: MS 89.95 months if delay was > 3 months; 190.40 months if wait was < 3 months (p 0.007). Conclusions: Low self consciousness of the patient; misdiagnosis or inadequate approach in general hospitals; late referral to specialized centres are 75% of the cause of wasted time. Organization problems at the referral Centre concur for 25% of delay. Guidelines implementation and educational programme among general population and PCP are necessary.

Download Full-text